17
Participants
Start Date
March 21, 2022
Primary Completion Date
January 31, 2024
Study Completion Date
January 31, 2024
ALVR106
Infusion, visually identical to placebo
Placebo
Infusion, visually identical to ALVR106
Roswell Park Comprehensive Cancer Center, Buffalo
Virginia Commonwealth University, Richmond
Wake Forest, Winston-Salem
University of North Carolina - Lineberger Comprehensive Cancer Center, Chapel Hill
Duke University Medical Center, Durham
Medical University of South Carolina, Charleston
Northside Hospital, Atlanta
University of Florida - Division of Hematology & Oncology, Gainesville
University of Miami - Sylvester Cancer Center, Miami
Vanderbilt University Cancer Center, Nashville
The Cleveland Clinic Foundation, Cleveland
University of Iowa, Iowa City
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
Baylor College of Medicine, Houston
MD Anderson Cancer Center, Houston
MD Anderson, Houston
Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale
City of Hope, Duarte
Fred Hutchinson Cancer Research Center, Seattle
University of Kansas Cancer Center, Kansas City
Dana Farber Cancer Institute, Boston
Lead Sponsor
AlloVir
INDUSTRY